Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience: British Journal of Haematology

I. Innocenti, F. Morelli, F. Autore, A. Piciocchi, A. Frustaci, F.R. Mauro, L. Schiattone, L. Trentin, G. Del Poeta, G. Reda, G.M. Rigolin, A. Ibatici, S. Ciolli, M. Coscia, P. Sportoletti, R. Murru, L. Levato, M. Gentile, G. D'Arena, D.G. EfremovA. Tedeschi, L. Scarfò, A. Cuneo, R. Foà, L. Laurenti

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Pages (from-to)e8-e11
JournalBr. J. Haematol.
Issue number1
Publication statusPublished - 2019


  • B-Cell receptor
  • chronic lymphocytic leukaemia
  • ibrutinib
  • idelalisib
  • venetoclax
  • cancer growth
  • cancer mortality
  • cancer survival
  • chronic lymphatic leukemia
  • controlled study
  • drug withdrawal
  • human
  • Italy
  • Kaplan Meier method
  • Letter
  • major clinical study
  • multiple cycle treatment
  • overall survival
  • priority journal
  • progression free survival
  • retrospective study
  • treatment duration
  • treatment outcome
  • unspecified side effect

Cite this